{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:52:00Z","timestamp":1785167520796,"version":"3.55.0"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,9,4]]},"published-print":{"date-parts":[[2024,11]]},"DOI":"10.2967\/jnumed.124.268101","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T21:05:38Z","timestamp":1727384738000},"page":"1769-1775","source":"Crossref","is-referenced-by-count":20,"title":["Preclinical Investigation of [<sup>212<\/sup>Pb]Pb-DOTAM-GRPR1 for Peptide Receptor Radionuclide Therapy in a Prostate Tumor Model"],"prefix":"10.2967","volume":"65","author":[{"given":"Amal","family":"Saidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania A.","family":"Stallons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy G.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien J.","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"key":"2025060410401060000_65.11.1769.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2025060410401060000_65.11.1769.2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0002-9378(89)90293-7","article-title":"The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma","volume":"160","author":"Rotmensch","year":"1989","journal-title":"Am J Obstet Gynecol."},{"key":"2025060410401060000_65.11.1769.3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pharmaceutics14010189","article-title":"212Pb: production approaches and targeted therapy applications","volume":"14","author":"Kokov","year":"2022","journal-title":"Pharmaceutics."},{"key":"2025060410401060000_65.11.1769.4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/ph8030416","article-title":"Toxicological studies of 212Pb intravenously or intraperitoneally injected into mice for a phase 1 trial","volume":"8","author":"Milenic","year":"2015","journal-title":"Pharmaceuticals (Basel)."},{"key":"2025060410401060000_65.11.1769.5","first-page":"1881","article-title":"Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice","volume":"40","author":"Tan","year":"2012","journal-title":"Int J Oncol."},{"key":"2025060410401060000_65.11.1769.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0619"},{"key":"2025060410401060000_65.11.1769.7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"Kasten","year":"2018","journal-title":"Nucl Med Biol."},{"key":"2025060410401060000_65.11.1769.8","doi-asserted-by":"crossref","unstructured":"Kasten BB Oliver PG Kim H . 212Pb-labeled antibody 225.28 targeted to chondroitin sulfate proteoglycan 4 for triple-negative breast cancer therapy in mouse models. Int J Mol Sci. 2018;19:925.","DOI":"10.3390\/ijms19040925"},{"key":"2025060410401060000_65.11.1769.9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1103"},{"key":"2025060410401060000_65.11.1769.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.239491"},{"key":"2025060410401060000_65.11.1769.11","doi-asserted-by":"crossref","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","article-title":"Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin\u2019s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003","volume":"15","author":"Maaland","year":"2020","journal-title":"PLoS One."},{"key":"2025060410401060000_65.11.1769.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2025060410401060000_65.11.1769.13","unstructured":"Phase 1 study of AlphaMedix\u2122 in adult subjects with SSTR (+) NET. ClinicalTrials.gov website. https:\/\/clinicaltrials.gov\/study\/NCT03466216?tab=results. Updated August 24, 2021. Accessed September 5, 2024."},{"key":"2025060410401060000_65.11.1769.14","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21434"},{"key":"2025060410401060000_65.11.1769.15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4149\/neo_2012_029","article-title":"Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor \u03b2cx in human prostate carcinoma","volume":"59","author":"Nagasaki","year":"2012","journal-title":"Neoplasma."},{"key":"2025060410401060000_65.11.1769.16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","article-title":"Prostate cancer theranostics targeting gastrin-releasing peptide receptors","volume":"20","author":"Baratto","year":"2018","journal-title":"Mol Imaging Biol."},{"key":"2025060410401060000_65.11.1769.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.188011"},{"key":"2025060410401060000_65.11.1769.18","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0679-OA"},{"key":"2025060410401060000_65.11.1769.19","first-page":"G655","article-title":"Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans","volume":"276","author":"Carroll","year":"1999","journal-title":"Am J Physiol."},{"key":"2025060410401060000_65.11.1769.20","doi-asserted-by":"crossref","first-page":"1126426","DOI":"10.3389\/fonc.2023.1126426","article-title":"Human gastrin-releasing peptide receptor expression in women with uterine cervix cancer","volume":"13","author":"Kunos","year":"2023","journal-title":"Front Oncol."},{"key":"2025060410401060000_65.11.1769.21","first-page":"707","article-title":"Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma","volume":"38","author":"Marrone","year":"2013","journal-title":"Clin Exp Dermatol."},{"key":"2025060410401060000_65.11.1769.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178889"},{"key":"2025060410401060000_65.11.1769.23","unstructured":"Safety and tolerability of 212Pb-DOTAM-GRPR1 in adult subjects with recurrent or metastatic GRPR-expressing tumors. NCI website. https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?id=NCI-2022-07733&r=1. Accessed September 5, 2024."},{"key":"2025060410401060000_65.11.1769.24","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/ijc.32401","article-title":"Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177Lu-DOTAGA-PEG2-RM26","volume":"145","author":"Mitran","year":"2019","journal-title":"Int J Cancer."},{"key":"2025060410401060000_65.11.1769.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.02.089"},{"key":"2025060410401060000_65.11.1769.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.141143"},{"key":"2025060410401060000_65.11.1769.27","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2025060410401060000_65.11.1769.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1596-9"},{"key":"2025060410401060000_65.11.1769.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.045054"},{"key":"2025060410401060000_65.11.1769.30","doi-asserted-by":"crossref","unstructured":"Wong K Sheehan-Dare G Nguyen A . 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen\/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a phase I trial. Pharmaceuticals (Basel). 2022;15:772.","DOI":"10.3390\/ph15070772"},{"key":"2025060410401060000_65.11.1769.31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.7150\/thno.13580","article-title":"In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:40:40Z","timestamp":1749058840000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.2967\/jnumed.124.268101"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268101","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,26]]}}}